Inactive Instrument

QSAM Biosciences, Inc.

Equities

QSAM

US74738N2027

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
8.3 ^USD	+7.10%		+3.75%	+36.07%

May. 03	Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	CI
Mar. 20	QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of Cyclosam(R) Targeting Metastatic Bone Cancer

March 08, 2023 at 08:00 am EST

QSAM Biosciences Inc. announced that the U.S. Food & Drug Administration (FDA) has cleared the Company's amended clinical trial protocol increasing the maximum age of participants to 75 years old from the prior age limitation of 65. This amendment to the enrollment criteria significantly expands the population of potential participants in QSAM's Phase 1 study evaluating CycloSam(R) in the treatment of bone cancer. older patients comprise a significant percentage of the current population of patients with metastatic bone cancer that is targeted by the CycloSam(R) drug product.

The FDA encourages sponsors to enroll participants who reflect the characteristics of clinically relevant populations, including age and sex, to allow for the collection of sufficient information pertaining to safety and effectiveness for product labeling.

Latest news about QSAM Biosciences, Inc.

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	May. 02	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	Nov. 13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	23-09-28	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	23-06-14	CI
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23-05-23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	23-04-26	CI
QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer	23-04-05	CI
QSAM Biosciences, Inc. announced that it has received $3 million in funding	23-03-30	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
QSAM Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of Cyclosam(R) Targeting Metastatic Bone Cancer	23-03-08	CI
QSAM Biosciences, Inc. Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	23-02-28	CI
QSAM Biosciences, Inc. Recruits the Ellis Fischel Cancer Center At the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam for Bone Cancer	23-02-22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
QSAM Biosciences, Inc Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer	22-10-26	CI
QSAM Biosciences, Inc. announced a financing transaction	22-09-29	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam	22-07-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
QSAM Biosciences, Inc. Announces the First Patient Commenced Treatment in Its Clinical Trial Evaluating Cyclosam® in Patients with Metastatic Bone Cancer	22-04-28	CI
QSAM Biosciences Inc. Receives Japanese Patent for Its Clinical Stage Radiopharmaceutical Drug Candidate, Cyclosam	22-04-12	CI

Chart QSAM Biosciences, Inc.

Duration

Period

More charts

Company Profile

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Companyâs technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.

Sector

More about the company